|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
7.040 USD |
-5.25% | -10.32% | -15.59% | |
April 07, 2025 at 08:24 am EDT
This article is reserved for members Unlock the article: REGISTER NOW!
© MT Newswires – 2025
|
Zevra Announces Closing Of Sale Of Rare Pediatric Disease Priority Review Voucher |
08:40am |
RE |
|
Zevra Therapeutics Nets $150 Million From US FDA Voucher Sale, Increases Cash Reserves |
08:24am |
MT |
|
Zevra Therapeutics Files Preliminary Proxy |
Mar. 31 |
RE |
|
Zevra Therapeutics Confirms Receipt of Director Nominees from Daniel J. Mangless |
Mar. 31 |
CI |
|
Zevra Therapeutics Asks Shareholders to Reject Director Nominees by Activist Investor |
Mar. 31 |
MT |
|
Sector Update: Health Care Stocks Lower Late Afternoon |
Mar. 12 |
MT |
|
Sector Update: Health Care Stocks Decline Wednesday Afternoon |
Mar. 12 |
MT |
|
Sector Update: Health Care |
Mar. 12 |
MT |
|
Zevra Therapeutics Q4 Net Loss Widens, Revenue Decreases; Shares Fall After Hours |
Mar. 11 |
MT |
|
Zevra Therapeutics, Inc., Q4 2024 Earnings Call, Mar 11, 2025 |
Mar. 11 |
|
|
Zevra Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 |
Mar. 11 |
CI |
|
Zevra Therapeutics to Sell Priority Review Voucher for $150 Million |
Feb. 27 |
MT |
|
Zevra Therapeutics to Sell Priority-Review Voucher for $150 Million |
Feb. 27 |
DJ |
|
An undisclosed buyer entered into a definitive asset purchase agreement to acquire Rare Pediatric Disease Priority Review Voucher of Zevra Therapeutics, Inc.. |
Feb. 26 |
CI |
|
Zevra Therapeutics Insider Sold Shares Worth $727,390, According to a Recent SEC Filing |
Feb. 14 |
MT |
|
Zevra Therapeutics, Inc.(NasdaqGS:ZVRA) added to NASDAQ Biotechnology Index |
Dec. 22 |
CI |
|
Zevra Therapeutics, Inc.(NasdaqGS:ZVRA) added to S&P Pharmaceuticals Select Industry Index |
Dec. 22 |
CI |
|
Zevra Therapeutics to Join Nasdaq Biotechnology Index |
Dec. 17 |
MT |
|
Zevra Therapeutics, Inc. Announces Departure of Executives |
Dec. 06 |
CI |
|
Zevra Therapeutics, Inc. Announces U.S. Commercial Availability of MIPLYFFA for Treatment of Niemann-Pick Disease Type C |
Nov. 21 |
CI |
|
Earnings Flash (ZVRA) ZEVRA THERAPEUTICS Reports Q3 Revenue $3.7M |
Nov. 12 |
MT |
|
Zevra Therapeutics, Inc., Q3 2024 Earnings Call, Nov 12, 2024 |
Nov. 12 |
|
|
Zevra Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 |
Nov. 12 |
CI |
|
Guggenheim Initiates Zevra Therapeutics With Buy Rating, $20 Price Target |
24-10-07 |
MT |
|
JMP Securities Initiates Zevra Therapeutics at Outperform |
24-09-24 |
MT |
ZVRA: Dynamic Chart
Zevra Therapeutics, Inc. is a rare disease company science, data, and patients need to create transformational therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company’s lead clinical development product candidate which is being developed as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep disorder, and narcolepsy. Its commercial product, AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder (ADHD), in patients aged six years and older containing its prodrug, serdexmethylphenidate (SDX), and d-methylphenidate (d-MPH). Its other commercial product is OLPRUVA.
More about the company
Buy
Last Close Price
7.040USD
Average target price
21.62USD
Spread / Average Target
+207.17%
Consensus
